Alcobra announces enrollment of first patient in Phase IIb clinical trial of MDX Alcobra announced that the first patient has been enrolled in a Phase IIb Fragile X study of MDX. The FDA granted "Orphan Drug" designation to Metadoxine in the treatment of Fragile X Syndrome in December 2013. The Phase IIb Fragile X trial is a multi-center, randomized, placebo-controlled study and is being conducted in 11 clinical sites, primarily in the U.S. It is designed to investigate MDX for 6 weeks compared with placebo in 60 adolescent and adult subjects with Fragile X Syndrome.
On The Fly: Analyst Initiation Summary Today's noteworthy initiations include: 8x8, Inc. (EGHT) initiated with a Buy at Summit Research... ARI Network (ARIS) initiated with an Outperform at Barrington... Alcobra (ADHD) initiated with an Outperform at Oppenheimer... CNO Financial (CNO) initiated with a Hold at Deutsche Bank... Expedia (EXPE) initiated with an Outperform at Wells Fargo... Gartner (IT) initiated with an Overweight at Atlantic Equities... MAG Silver (MVG) initiated with a Buy at Roth Capital... Mitek Systems (MITK) initiated with an Outperform at Northland... Priceline (PCLN) initiated with a Market Perform at Wells Fargo... QTS Realty Trust (QTS) initiated with a Buy at SunTrust... Seres Therapeutics (MCRB) initiated with a Buy at H.C. Wainwright.